Please join CureSearch for Children’s Cancer and Healthspottr for CureSearch Catapult 2016.
This invitational gathering is a rare opportunity for innovative researchers in the field of pediatric oncology to privately engage with leaders from pharma and biotech, experts in health policy and regulation, venture and philanthropic investors, and with thought-leading entrepreneurs and business service professionals. Through insightful debates and keynotes, small workshops and curated networking in an intimate setting, our day-and-a-half program seeks to discover new opportunities for collaboration between our funded researchers and these industry stakeholders so that we may establish a new roadmap for accelerating novel treatments to children in the clinic.
This event is made possible by the financial support of our sponsors and partners
WELCOME REMARKS | CureSearch President and CEO Laura S. Thrall
PANEL DISCUSSION | Why Catapult: Fording the Valley of Death
Carleen Hawn, CEO, Healthspottr
Our program moderator will describe the goals for the day, desired outcomes and our rules of engagement.
Dr. L. Mary Smith, Vice President of Product Development, United Therapeutics
Representatives of invited companies share strategically important lessons from a previous development project. Dr. Smith will discuss the strategy evolution that helped bring Unituxin to fruition for United Therapeutics. How might this development formula inform CureSearch investigators’ work? Includes Q&A.
Dr. Raphaël Rousseau, Global Development Team Leader, Pediatrics, Genentech
The Matrix: Clinical Trial Innovation in Pediatric Oncology
Dr. Martha Donoghue, Pediatric Solid Tumors Scientific Liaison, United States Food and Drug Administration
Dr. Ralf Herold, Senior Scientific Officer, European Medicines Agency (via video conference)
Nancy Goodman, Founder and Executive Director, Kids v Cancer
Moderated by Carleen Hawn
Entrepreneurs at the leading edge of research, genomics and targeted therapeutics debate the new models and methods for accelerating potential cures to children in the clinic. In conversation with Jonathan Hirsch, Dr. Ethan Perlstein and Dr. Kevin Grimes.
Q&A moderated by Carleen Hawn.
Kenneth Schaner, Partner, Schaner & Lubitz PLLC
Representatives of invited companies share strategically important lessons from successful projects or companies. Kenneth Schaner, of Schaner & Lubitz PLLC, offers insights from his decades-long career facilitating successful partnerships between innovative researchers, commercial industry players and venture philanthropy investors. What can academic researchers focused on orphan diseases learn from these unique, three-pronged partnerships?
In conversation with CureSearch President and CEO Laura S. Thrall. Includes Q&A.
Working in two groups, participants will identify immediate opportunities to leverage our collective resources to help grantees clear a current development hurdle.
WORKSHOP A | Accelerating a Novel LSD-1 Inhibitor to Pediatric Clinical Trials for Ewing Sarcoma
WORKSHOP B | Driving Tumor Paint towards FDA Approval for Pediatric Brain Cancer